Skip to content

Leptin in Human Energy and Neuroendocrine Homeostasis

Leptin in Human Energy and Neuroendocrine Homeostasis

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00265980
Enrollment
22
Registered
2005-12-15
Start date
2002-07-31
Completion date
2013-07-31
Last updated
2019-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Weight Loss

Keywords

Leptin, Obesity, Energy, Autonomics, Neuroendocrine

Brief summary

Previous work in our laboratory, and many others, has shown that body weight is regulated. When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow metabolic rate thus favoring the regain of lost weight. Individuals with leptin deficiency are remarkably similar to weight-reduced individuals. Their metabolism, thyroid hormones, and sympathetic nervous system activity are all low despite their obesity. While administration of leptin to leptin-deficient humans results in substantial weight loss and increases in energy expenditure. However, leptin administration to leptin-sufficient humans at usual body weight has little or no effect on weight unless given in doses 10-20 times what would be considered to be in the normal physiological range. This study examines the hypothesis that leptin is read by various systems regulating energy balance as an indicator of how much energy we have stored and that the body perceives the weight-reduced state as a condition of relative leptin insufficiency. Within this model, restoration of leptin to levels present prior to weight loss should relieve much of the metabolic opposition to keeping weight off. Preliminary studies support this hypothesis.

Detailed description

The failure of obesity treatments to sustain weight reduction is widely recognized. The central hypotheses of these studies are that: 1) Energy and neuroendocrine homeostatic systems are altered during the maintenance of a reduced body weight in a manner that favors weight regain; 2) These changes occur because weight-reduced individuals are in a state of relative leptin deficiency due to loss of body fat; and 3) Therefore these changes accompanying the maintenance of a reduced body weight will be reversed if circulating leptin concentrations are restored to those that were present prior to weight reduction. Maintenance of a reduced body weight is associated with integrated autonomic and neuroendocrine changes that reduce energy expenditure and increase food intake in a manner that is similar to that seen in rodents and humans who are deficient in, or resistant to, the adipocyte-derived hormone leptin. Systemic leptin administration to leptin-deficient rodents and humans reverses the metabolic (hypometabolism, hyperphagia), autonomic (increased parasympathetic and decreased sympathetic nervous system tone), and neuroendocrine changes that characterize the leptin-deficient state. The proposed studies focus on the neuroendocrine, autonomic, and metabolic changes that characterize the reduced-obese individual, and the effects on these phenotypes of restoration of circulating concentrations of leptin to levels present prior to weight loss. Healthy lean and overweight subjects are admitted to the General Clinical Research Center at Columbia University Medical College and placed on a liquid formula diet. Calories are adjusted until weight is stable and then subjects undergo testing of neuroendocrine, autonomic, and metabolic function. All subjects undergo an in-patient 10% weight reduction. Subjects are studied in a single blind placebo control design in which they are studied at usual weight and while maintaining a 10% reduced weight. At either usual weight or reduced state subjects undergo a single blind crossover placebo/control study in which they receive placebo, leptin injections while on an isocaloric diet either at usual weight or following a 10% weight loss. During each of these study periods, subjects will undergo detailed evaluation of 1) energy expenditure; 2) autonomic nervous system tone (serial blockade of sympathetic and parasympathetic inputs, heart rate variability analyses, and urinary catecholamine excretion); 3) hypothalamic-pituitary-thyroid, -adrenal and -gonadal, axis function; 4) adipose tissue gene expression; 5) other molecules (e.g., adiponectin, ghrelin, PYY) that may influence neuroendocrine and metabolic function. The results of these studies will further delineate the physiology of body weight regulation and of leptin.

Interventions

Twice daily injections of saline in the same volume as will be used for leptin injections.

DRUGLeptin

Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Columbia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

Randomized, single-blind, crossover study: half of the subjects had placebo first and half had leptin first. The order does not affect data analysis.

Eligibility

Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy lean or overweight males and females who have sustained their current weight for at least 6 months.

Exclusion criteria

* Pregnancy * Any illness or chronic medication that affect energy expenditure, neuroendocrine function, autonomic function or that would impair ability to tolerate a prolonged hospital stay including rapid weight reduction and vigorous exercise.

Design outcomes

Primary

MeasureTime frameDescription
Total Energy Expenditure (TEE)Baseline, 11 weeks, 18 weeksTo measure the metabolic changes associated with maintenance of a reduced body weight (in kcal/day)

Secondary

MeasureTime frameDescription
TEE/FFMBaseline, 11 weeks, 18 weeksTo measure the total energy expenditure/fat-free mass (FFM) (in kcal/kg).

Countries

United States

Participant flow

Participants by arm

ArmCount
Leptin Depletion Study Participants (Total)
Each of the 22 participant went through the stages (arms) of obtaining the initial weight (Weight Initial), reducing weight maintenance (placebo injection), and repletion of leptin (leptin injection).
22
Total22

Baseline characteristics

CharacteristicLeptin Depletion Study Participants (Total)
Age, Customized
Age
34.2 years
STANDARD_DEVIATION 8.1
Fa-free mass (FFM)62.4 kg
STANDARD_DEVIATION 14.3
Region of Enrollment
United States
22 participants
Sex: Female, Male
Female
13 Participants
Sex: Female, Male
Male
9 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 22
other
Total, other adverse events
0 / 22
serious
Total, serious adverse events
0 / 22

Outcome results

Primary

Total Energy Expenditure (TEE)

To measure the metabolic changes associated with maintenance of a reduced body weight (in kcal/day)

Time frame: Baseline, 11 weeks, 18 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Leptin Depletion Study Participants (Total)Total Energy Expenditure (TEE)Weight initial3131 kcal/dayStandard Deviation 500
Leptin Depletion Study Participants (Total)Total Energy Expenditure (TEE)Weight -10% placebo2457 kcal/dayStandard Deviation 410
Leptin Depletion Study Participants (Total)Total Energy Expenditure (TEE)Weight -10% leptin2766 kcal/dayStandard Deviation 799
Secondary

TEE/FFM

To measure the total energy expenditure/fat-free mass (FFM) (in kcal/kg).

Time frame: Baseline, 11 weeks, 18 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Leptin Depletion Study Participants (Total)TEE/FFMWeight initial51.1 kcal/kgStandard Deviation 6.3
Leptin Depletion Study Participants (Total)TEE/FFMWeight -10% placebo41.7 kcal/kgStandard Deviation 6.2
Leptin Depletion Study Participants (Total)TEE/FFMWeight -10% leptin48.1 kcal/kgStandard Deviation 12.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026